Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Seeking Alpha

22 Jun 2026, 18:42 UTC · 2h ago

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

Which stocks this story touches

How each ticker is affected

MLTX+0.50
The transcript of an Analyst/Investor Day typically provides a platform for the company to present its growth strategy and pipeline progress.

Read original · https://seekingalpha.com/article/4916730-moonlake-immunotherapeutics-mltx-analyst-investor-day-transcript

Free · No account

Track these names every morning.

Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.

We’ll watch

$MLTX#biotech#clinical_trials#drug_pipeline#immunology

Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.

Free forever · one email a day, max · unsubscribe in one click.How it works

How the impact breaks down

Where the story's weight lands

Impact by category

Sector Rotation+0.200

6 related stories

Seeking Alpha
31m ago
Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript
- biotech
- drug pipeline
Read

MoonLake Immunotherapeuti… — MLTX +0.50 | NewsImpactScreener

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

How each ticker is affected

Track these names every morning.

Impact by category

Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

How each ticker is affected

Track these names every morning.

Impact by category

Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript

Biggest drivers

Most positively impacted

Most negatively impacted

Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy

WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer

Insmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buy

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

How each ticker is affected

Track these names every morning.

Impact by category

Next reads from the same story arc

Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

How each ticker is affected

Track these names every morning.

Impact by category

Next reads from the same story arc

Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript

Biggest drivers

Most positively impacted

Most negatively impacted

Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy

WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer

Insmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buy

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)